Top Story

FDA grants breakthrough therapy designation to JCAR015 for ALL

November 24, 2014

The FDA granted breakthrough therapy designation to JCAR015, a chimeric antigen receptor-modified T-cell therapy candidate, for the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia who have not received prior therapy, according to the manufacturer.

Originally developed for treatment of patients with aggressive B-cell non-Hodgkin’s lymphoma, JCAR015 (Juno Therapeutics) is designed to target CD19, identified on most B-cell malignancies, including various subtypes of NHL and ALL.

Meeting News Coverage

American Indians, Alaskan Natives experienced shorter cancer survival, even with equal access to care

November 21, 2014
Cancer survivors of American Indian or Alaskan Native descent demonstrated poorer rates of 5- and 10-year cancer survival than non-Hispanic whites even when they had…
FDA News

FDA grants orphan drug status to BGB324 for AML

November 19, 2014
The FDA granted orphan drug designation to BGB324 for the treatment of patients with acute myeloid leukemia, its manufacturer announced recently.Based on preclinical…
FDA News

FDA grants orphan drug status to JCAR015 for ALL treatment

November 18, 2014
The FDA granted orphan drug designation to JCAR015, a chimeric antigen receptor-modified T-cell therapy candidate, for the treatment of patients with acute lymphoblastic…
CME
Hot melanoma

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Video
thumbnail for video 3867608936001

CTL019 therapy induced sustained remission in relapsed, refractory ALL

October 30, 2014
PHILADELPHIA — David L. Porter, MD, director of blood and marrow transplantation at Abramson Cancer Center at…
More »
CME CNE
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS: Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
FDA News

FDA grants breakthrough therapy designation to JCAR015 for ALL

November 24, 2014
The FDA granted breakthrough therapy designation to JCAR015, a chimeric antigen receptor-modified T-cell therapy candidate, for the treatment of…
Meeting News Coverage

American Indians, Alaskan Natives experienced shorter cancer survival, even with equal access to care

November 21, 2014
Cancer survivors of American Indian or Alaskan Native descent demonstrated poorer rates of 5- and 10-year cancer survival than non-Hispanic whites…
FDA News

FDA grants orphan drug status to BGB324 for AML

November 19, 2014
The FDA granted orphan drug designation to BGB324 for the treatment of patients with acute myeloid leukemia, its manufacturer announced…
FDA News

FDA grants orphan drug status to JCAR015 for ALL treatment

November 18, 2014
The FDA granted orphan drug designation to JCAR015, a chimeric antigen receptor-modified T-cell therapy candidate, for the treatment of patients with…
Paul Richardson In the Journals

Allogeneic transplantation achieved graft-versus-myeloma effect

November 18, 2014
Allogeneic transplantation induced sustained remissions in patients with multiple myeloma, with the greatest survival benefit observed among those…
In the JournalsPerspective

Outcomes in primary myelofibrosis varied greatly based on mutation status

November 17, 2014
Driver mutations of JAK2, MPL and the calreticulin gene further divided primary myelofibrosis into distinct subtypes, and outcomes such as disease…
In the Journals

ATRA plus arsenic trioxide improved quality of life in acute promyelocytic leukemia

November 13, 2014
Patients with acute promyelocytic leukemia who underwent front-line treatment with all-trans–retinoic acid plus arsenic trioxide demonstrated…
Lenalidomide plus rituximab induced high response rate in untreated indolent lymphoma In the Journals

Lenalidomide plus rituximab induced high response rate in untreated indolent lymphoma

November 11, 2014
The combination of lenalidomide plus rituximab appeared highly active in patients with treatment-naive indolent non-Hodgkin’s lymphoma, according to…
In the Journals

Nearly one-third of AYA patients do not receive adequate cancer therapy

November 7, 2014
About 30% of adolescents and young adults with cancer do not receive appropriate initial treatment, according to study results.Arnold L. Potosky
CTL019 therapy may significantly alter treatment of hematologic malignancies CommentaryVideo

CTL019 therapy may significantly alter treatment of hematologic malignancies

November 7, 2014
PHILADELPHIA — David L. Porter, MD, director of blood and marrow transplantation at Abramson Cancer Center at the University of Pennsylvania…
More Headlines »
morganatic-roan
morganatic-roan